Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Live Chat available weekdays, 7:00 am - 6:30 pm CT
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
- Referrals to patient-related programs or resources
- Donations, website, or event-related assistance
- Tobacco-related topics
- Volunteer opportunities
- Cancer Information
For medical questions, we encourage you to review our information with your doctor.
Chronic Myelomonocytic Leukemia (CMML)
- Signs and Symptoms of Chronic Myelomonocytic Leukemia (CMML)
- Tests for Chronic Myelomonocytic Leukemia (CMML)
- Chronic Myelomonocytic Leukemia (CMML) Subtypes, Stages, and Risk Groups
- Survival Rates for Chronic Myelomonocytic Leukemia (CMML)
- Questions to Ask Your Doctor About Chronic Myelomonocytic Leukemia (CMML)
- Supportive Therapy for People with Chronic Myelomonocytic Leukemia (CMML)
- Chemotherapy for Chronic Myelomonocytic Leukemia (CMML)
- Radiation Therapy for Chronic Myelomonocytic Leukemia (CMML)
- Surgery for Chronic Myelomonocytic Leukemia (CMML)
- Stem Cell Transplant for Chronic Myelomonocytic Leukemia (CMML)
- General Approach to Treating Chronic Myelomonocytic Leukemia (CMML)
General Approach to Treating Chronic Myelomonocytic Leukemia (CMML)
Treatment for people with chronic myelomonocytic leukemia (CMML) depends on a number of factors, such as:
- A person's age and overall health (including if they are eligible for a stem cell transplant)
- Whether the CMML is causing symptoms and how fast it seems to be progressing
- Whether the CMML is in a higher or lower risk group
- A person's preferences and goals for treatment
Treating CMML if a stem cell transplant can be done
In general, a stem cell transplant (SCT) is the only realistic way to try to cure CMML. Other treatments aim to treat symptoms caused by the CMML and possibly slow its progression.
Stem cell transplant is often the treatment of choice for younger people with higher-risk CMML, if a matched stem cell donor is available. Because of advances in SCT, this treatment might also be an option for some older people.
In general, SCT hasn't shown to be better than other treatments for people with lower-risk CMML.
Treating CMML if stem cell transplant is not an option
If SCT isn’t an option, the main goal of treatment is to relieve symptoms from the CMML while also limiting complications and reducing side effects.
Supportive care is used to treat all people with CMML, so they can live as well as possible. This type of care can include transfusions, blood cell growth factors, and antibiotics to treat infections.
For people who aren't having symptoms from CMML, treatment might not be needed right away. Instead, doctors may just watch the CMML closely.
If treatment is needed, chemotherapy is typically the first choice. This is done with either hydroxyurea or one of the hypomethylating agents (azacitidine or decitabine). The choice often depends on the types of symptoms a person is having and whether those symptoms need to be controlled.
For example:
- A major benefit of azacitidine or decitabine is a reduced need for blood transfusions and an improved quality of life. If the CMML responds, people are often less fatigued and can function more normally.
- Treatment with hydroxyurea can help some people with high white blood cell counts. This drug can help lower monocyte counts and decrease the need for transfusions. It can also shrink the spleen to help a person feel more comfortable.
If one type of drug doesn't work, another can often be tried.
Because CMML can often be hard to treat, taking part in a clinical trial testing a newer treatment might be a good option for some people.
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
National Cancer Institute. Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version. 2024. Accessed at https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq on January 27, 2025.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Myelodysplastic Syndromes. Version 2.2025. Accessed at https://www.nccn.org on January 27, 2025.
Padron E. Chronic myelomonocytic leukemia: Management and prognosis. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/chronic-myelomonocytic-leukemia-management-and-prognosis on January 27, 2025.
Sekeres MA, Platzbecker U. Treatment of lower-risk myelodysplastic syndromes/neoplasms (MDS). UpToDate. 2025. Accessed at https://www.uptodate.com/contents/treatment-of-lower-risk-myelodysplastic-syndromes-neoplasms-mds on January 27, 2025.
Last Revised: March 7, 2025
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.